Gene expression signatures associated with sensitivity to azacitidine in myelodysplastic syndromes.
Ontology highlight
ABSTRACT: Allogeneic stem cell transplantation is currently the only curative treatment option for myelodysplastic syndromes (MDS). Pre-transplant debulking treatment have been employed for advanced MDS and we previously reported that marrow response (blast ≤ 5%) following the bridging therapy with hypomethylating agent was an independent favorable factor for survival; however, it is still not clear which patients will respond to hypomethylating agent and which genomic features can predict the response. In this study, we performed RNAseq for 23 MDS patients among which 14 (61%) and 9 (39%) patients showed marrow complete remission and primary resistance to azacitidine, respectively. Differential expression-based analyses of treatment-naive, baseline gene expression profiles revealed that molecular f
SUBMITTER: Kim K
PROVIDER: S-EPMC7658235 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA